Robust pipeline with around 50 projects in clinical development / Cardiology portfolio poised for growth with launch products Kerendia™ (finerenone) and Verquvo™ (vericiguat) / Gearing up to become top-10 oncology company by 2030 with prostate cancer treatment Nubeqa™ (darolutamide) as a key driver for future growth / Expanding into the fast-evolving medical imaging AI market, building on leading expertise in radiology and medical understanding across various diseases / Leading portfolio and long-standing commitment in women’s healthcare, with progress in late-stage clinical trials and significant investments in sustainability
At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.
“We are taking bold steps into the future of drug development, investing strongly in areas at the forefront of the biomedical and technological revolution. Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division. “We are excited to see our efforts crystalize in our latest product launches, which include two potential blockbusters, as well as a late-stage portfolio with at least another blockbuster opportunity.”
Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies. The company is advancing around 50 projects in ongoing clinical trials across a range of potential therapeutic modalities and indications, with a focus on oncology, cardiovascular and women’s health.
Strong pipeline with robust late-stage development program and broad potential across indications
In the area of cardiovascular disease, Bayer is delivering on its late-stage pipeline including recent launches of Kerendia™ (finerenone) and Verquvo™ (vericiguat).
“We are currently in the remarkable position to launch several important new medicines in parallel, and we are unlocking the full potential of our assets through systematic data generation, multi-indication approaches as well as building on new digital business models,” said Christian Rommel, Member of the Executive Committee of Bayer’s Pharmaceutical Division and Head of Research and Development. “Our scientific leadership in the area of cardiovascular diseases advances our mission to provide better treatment options for patients in need.”
Bayer’s efforts in oncology focus on differentiated approaches that have the potential to fundamentally impact the way that cancer is treated. With three product launches over the last five years, Bayer has significantly broadened its footprint in the area, focusing on those areas with the highest unmet medical need while applying a broad range of modalities.
Re-imagining Radiology
Bayer is strongly positioned in the fast-growing medical imaging artificial intelligence (AI) market, combining a long-term expertise in radiology with a deep understanding of patients’ and physicians’ needs across a broad range of diseases, from oncology to cardiovascular, resulting in the ability to provide know-how and solutions from diagnosis to care.
In times of limited resources in healthcare systems, growing as well as aging populations and changing lifestyles contribute to an increase in chronic conditions such as cardiovascular disease and cancer. As a result, the need for tools delivering improved diagnostic information while helping save costs and time is increasing. Tackling this challenge with advanced technologies and products, radiology is a key enabler to transform healthcare, expanding personalized medicine and improving outcomes for patients. In particular, AI bears vast potential for advancing radiology.
Bayer is developing a platform through which healthcare professionals can centrally manage AI-enabled medical imaging and imaging workflow applications. These solutions are being developed by Bayer as well as third parties, and aim to support the complex decision-making processes of healthcare professionals in their task to provide a clear direction from diagnosis to care for their patients.
Shaping women’s health from menarche to menopause
Bayer has a long-standing commitment to delivering solutions to meet women’s needs across the different stages of their lives. While pursuing research to find new treatment options for gynecological diseases with a high unmet medical need, the company is also working on addressing women’s health needs during menopause. Elinzanetant, a non-hormonal development compound, is currently being investigated in the Phase III clinical development program OASIS for the treatment of vasomotor symptoms during menopause.
“Every year 47 million women enter menopause, a period where women are at the peak of their life’s activity, personally and professionally. With increased longevity, maintaining functional ability and good quality of life is extremely relevant from both a healthcare and a socio-economic perspective. Unfortunately, menopause remains a taboo topic, leaving many women untreated,” said Cecilia Caetano, MD, Head of Medical Affairs Menopause at Bayer. “With our strong heritage and deeply rooted expertise in women’s health, we continue to focus on providing innovative science, solutions and education to support the individual health need of women.”
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros.
Source link:https://media.bayer.com/
